It’s not too late for flu vaccination

**It’s not too late for flu vaccination — and this season the "Super Flu is going around.** Medscape recently interviewed **Lisa Grohskopf, MD, MPH**, from the CDC’s Influenza Division, who outlined two major changes for the 2024–2025 influenza season: 🔹 **All U.S. flu vaccines are now trivalent**, targeting A(H1N1), A(H3N2), and B/Victoria. The B/Yamagata component has been removed, as it disappeared from global circulation in 2020. 🔹 **ACIP now recommends high‑dose or adjuvanted inactivated vaccines as acceptable options for adult solid organ transplant recipients (18–64)**, reflecting evidence of stronger immunogenicity in this population. Dr. Grohskopf also reinforced that **everyone aged ≥6 months** should receive an annual flu vaccine, with special emphasis on adults ≥65, young children, and individuals with chronic conditions. And importantly: **vaccination remains valuable well beyond October**. Protection develops in about two weeks, and flu activity typically peaks in December, January, or later. Coverage still hasn’t returned to pre‑COVID levels — a reminder that **strong provider recommendations matter**. The CDC’s SHARE framework remains a powerful tool for guiding patient conversations. --- ### **For diagnostics leaders navigating this season’s respiratory landscape:** The **GRN IVD Consulting Point‑of‑Care Market Report** delivers a clear, data‑driven view of platform performance, competitive positioning, and market dynamics across influenza and broader respiratory testing. If you support strategic decisions in POC diagnostics, this report is built for you.